NCT04796714 AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
| NCT ID | NCT04796714 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Hospital, Bordeaux |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-10-03 |
| Primary Completion | 2027-05-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2022-10-03 with a primary completion date of 2027-05-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF). The primary objective of the study is to evaluate the efficacy of Aspirin versus Aspirin + Clopidogrel after LAAC by comparing the occurrence of ischemic lesions on cerebrovascular magnetic resonance imaging (MRI) studies.
Eligibility Criteria
Inclusion Criteria: * Male or female patients with LAAC indication according to "Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé" (CNEDiMTS) (National Commission for the Evaluation of Medical Devices and Health Technologies) guidelines * Age ≥ 18 years * Written informed consent provided by the patient * Heart team approval: multidisciplinary team including interventional cardiologists, neurologists and other physicians discussing the definitive contraindication for anticoagulation * Registration under social security system Exclusion Criteria: * Minors * Unacceptable bleeding risk with double antiplatelet therapy decided by the physician who contraindicated oral anticoagulation * LAAC contraindication : left appendage thrombus * Major disease resulting in a life expectancy of \< 1 year * Severe and inherited bleeding disorder * Known hypersensitivity to aspirin and/or clopidogrel: * Hypersensitivity to clopidogrel, acetylsalicylic acid, or one of the excipients or other nonsteroidal anti-inflammatory drugs (cross-reaction). * Asthma or a history of asthma with or without nasal polyps induced by salicylates or substances of close activity, including nonsteroidal anti-inflammatory drugs. * Evolving peptic ulcer or history of gastric hemorrhage or perforation after treatment with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs. * Any constitutional or acquired haemorrhagic disease. * Patients with mastocytosis, in whom the use of acetylsalicylic acid can lead to severe hypersensitivity reactions (including circulatory shocks with flushing, hypotension, tachycardia and vomiting). * Severe liver failure. * Severe kidney failure (Creatinine light \< 30ml/min). * Uncontrolled severe heart failure * Contraindication to MRI: claustrophobia or inability to lie still for exam time, implantable pacemaker or defibrillator, intracorporeal metal foreign body (especially intraocular), intracranial metal clip, cochlear implant, cardiac valve prosthesis type Starr-Edwards pre 6000, or biomedical device type insulin pump or neurostimulator. * Guardianship * Curatorship * Pregnancy or child-bearing potential female * Woman of childbearing age who does not benefit from highly effective contraception (CTFG recommendation on highly effective contraceptive methods: oral, intravaginal or transdermal estrogeno-progestin contraception; progestin-based oral, injectable or implantable contraception; intrauterine device; hormonal intrauterine device; female sterilization (occlusion of the fallopian tubes)) * Iode contraindication * Patient already participating in another category 1 interventional research * Patient in a period of exclusion relative to another research protocol.
Contact & Investigator
Zakaria JALAL, MD
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT04796714 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04796714 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT04796714 currently recruiting?
Yes, NCT04796714 is actively recruiting participants. Contact the research team at zakaria.jalal@chu-bordeaux.fr for enrollment information.
Where is the NCT04796714 trial being conducted?
This trial is being conducted at Pessac, France, Toulouse, France.
Who is sponsoring the NCT04796714 clinical trial?
NCT04796714 is sponsored by University Hospital, Bordeaux. The principal investigator is Zakaria JALAL, MD at University Hospital, Bordeaux. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.